This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (74)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Elisabeth Ryzen, MD; Raymond R. Martodam, PhD; Mark Troxell, MD; Al Benson, MD; Alexander Paterson, MD; Kirk Shepard, MD; Richard Hicks

Arch Intern Med. 1985;145(3):449-452.

Abstract
• The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2,3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3±2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non—small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.

(Arch Intern Med 1985;145:449-452)

Author Affiliations
From the Orthopedic Hospital, Los Angeles (Dr Ryzen); Department of Oncology, Brooke Army Medical Center, San Antonio, Tex (Dr Troxell); Department of Human Oncology, University of Wisconsin, Madison (Dr Benson); Cross Cancer Institute, Edmonton, Alberta (Dr Paterson); Division of Hematology/Oncology, University of Chicago Hospital and Clinics (Dr Shepard); and Proctor & Gamble Co, Cincinnati (Dr Martodam and Mr Hicks).

Footnotes
Accepted for publication July 8, 1984.

Reprint requests to Proctor & Gamble Co, PO Box 39175, Cincinnati, OH 45247 (Dr Martodam).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Malignant Hypercalcemia: The Choice of Therapy
List
Arch Intern Med 1991;151:437-438.
ABSTRACT  

Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study
Singer et al.
Arch Intern Med 1991;151:471-476.
ABSTRACT  

Effects of a New Aminodiphosphonate (Aminohydroxybutylidene Diphosphonate) in Patients With Osteolytic Lesions From Metastases and Myelomatosis: Comparison With Dichloromethylene Diphosphonate
Attardo-Parrinello et al.
Arch Intern Med 1987;147:1629-1633.
ABSTRACT  

Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia
Schiller et al.
Arch Intern Med 1987;147:963-966.
ABSTRACT  

Treatment of Cancer-Associated Hypercalcemia With Cisplatin
Lad et al.
Arch Intern Med 1987;147:329-332.
ABSTRACT